Simplicity Wealth LLC Acquires Shares of 24,210 Kenvue Inc. $KVUE

Simplicity Wealth LLC acquired a new stake in Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 24,210 shares of the company’s stock, valued at approximately $507,000.

Other institutional investors also recently modified their holdings of the company. Pittenger & Anderson Inc. bought a new stake in shares of Kenvue in the first quarter valued at about $30,000. TruNorth Capital Management LLC bought a new stake in shares of Kenvue in the first quarter valued at about $36,000. Truvestments Capital LLC bought a new stake in shares of Kenvue in the first quarter valued at about $37,000. Trust Co. of Vermont boosted its position in shares of Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after acquiring an additional 1,150 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after acquiring an additional 1,287 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 3.3%

KVUE stock opened at $16.21 on Wednesday. The stock has a market capitalization of $31.10 billion, a P/E ratio of 21.90, a price-to-earnings-growth ratio of 2.25 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $15.47 and a 12 month high of $25.17. The firm has a 50-day moving average price of $19.46 and a 200-day moving average price of $21.46.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were paid a $0.2075 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a dividend yield of 5.1%. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s payout ratio is currently 112.16%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on KVUE shares. Rothschild & Co Redburn raised shares of Kenvue from a “neutral” rating to a “buy” rating and reduced their target price for the company from $22.50 to $22.00 in a research report on Friday, September 26th. UBS Group cut their price objective on shares of Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday, July 17th. Canaccord Genuity Group cut their price objective on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Barclays cut their price objective on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 1st. Finally, Bank of America cut their price objective on shares of Kenvue from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $22.46.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.